Coronavirus (19) Patents, Filed Since 1984

 

Coronavirus has 19 distinctive patents that had been filed earlier than the outbreak commenced dating back to 1984. Is this proof of a false flag or manufactured outbreak?

Patended viruses are big bucks for the pharmaceutical industry. As of March 20, 2020, one industry source catalogs no fewer than fifty different vaccines, diagnostics, and treatments that are being developed and tested for the COVID-19 coronavirus around the world.  Many of these technologies were originally targeted at other diseases including malaria, rheumatoid arthritis, hepatitis C, influenza, Marburg virus, Ebola, Middle East Respiratory Syndrome (MERS), severe acute respiratory syndrome (SARS), and human immunodeficiency virus (HIV). As a result, there is already a large body of scientific literature addressing many of the underlying compounds, and many are covered by existing patents and patent applications (collectively “patents”). One recent study by the American Chemical Society identified over 2,000 patents relating to SARS and MERS treatments alone. These patents are held by a range of companies and institutions across North America, Asia, and Europe.  In addition to these, a large number of patents cover the manufacture, operation, and components of devices and equipment that are used to treat the symptoms of coronavirus, and to monitor and prevent its spread, including respirators, ventilators, diagnostic kits, facial masks, software, mobile apps, and the like.

corona, stamp, pass

Historically, the Deep State and large pharma appear to discover a new virus, or two, each and every 12 months to drum up an ocean of fear, paranoia, and anxiety. Do you have in mind SARS, ZIKA, and Avian Flu?

Is there a precedent that drug agencies make gobs of cash from fitness scares like this?

In her 1994 book, Disease Mongers, Lynn Prayers makes the case that the for-profit healthcare business, from meals to doctors, to insurance, to drug companies, work hand-in-glove to make sure massive profits.

How?

By growing concern around a health problem so you go out and purchase what they’re selling.

How do they do this?

Through mass media.

Here’s the listing of 19 I discovered, courtesy of usahitman.com:

Below is a listing of patents which deal with this ‘”not-so” new’ coronavirus. We understand how most of these viruses are lab-created and this offers some extra attain or statistics to research!

covid-19, coronavirus, quarantine

fernandozhiminaicela (CC0), Pixabay

  1. CORONAVIRUS PROTEINS AND ANTIGENS Publication number: 20160339097 Abstract: Disclosed herein are embodiments of a method for collecting, extracting or eluting proteins and antigens from cells infected with coronavirus. The coronavirus may be a porcine coronavirus, such as porcine epidemic diarrhea virus (PEDV) or porcine delta coronavirus (PDCoV). Also disclosed are embodiments of a composition comprising the coronavirus proteins and antigens, and embodiments of a method of using such a composition. Applications for the composition include, but are not limited to, use in the preparation of antibodies against the proteins and antigens, use as reference markers for coronavirus proteins, and/or use in an immunogenic composition, such as in a vaccine composition. Type: Application Filed: August 4, 2016 Publication date: November 24, 2016 Applicant: MJ Biologics, Inc. Inventor: Byoung-Kwan Kim.
  2. CORONAVIRUS PROTEINS AND ANTIGENS  Publication number: 20190202868 Abstract: Disclosed herein are embodiments of a method for collecting, extracting or eluting proteins and antigens from cells infected with coronavirus. The coronavirus may be a porcine coronavirus, such as porcine epidemic diarrhea virus (PEDV) or porcine delta coronavirus (PDCoV). Also disclosed are embodiments of a composition comprising the coronavirus proteins and antigens, and embodiments of a method of using such a composition. Applications for the composition include, but are not limited to, use in the preparation of antibodies against the proteins and antigens, use as reference markers for coronavirus proteins, and/or use in an immunogenic composition, such as in a vaccine composition. Type: Application Filed: March 15, 2019 Publication date: July 4, 2019 Applicant: Phibro Animal Health Corporation Inventor: Byoung-Kwan Kim.
  3. Coronavirus proteins and antigens Patent number: 10280199 Abstract: Disclosed herein are embodiments of a method for collecting, extracting or eluting proteins and antigens from cells infected with coronavirus. The coronavirus may be a porcine coronavirus, such as porcine epidemic diarrhea virus (PEDV) or porcine delta coronavirus (PDCoV). Also disclosed are embodiments of a composition comprising the coronavirus proteins and antigens, and embodiments of a method of using such a composition. Applications for the composition include, but are not limited to, use in the preparation of antibodies against the proteins and antigens, use as reference markers for coronavirus proteins, and/or use in an immunogenic composition, such as in a vaccine composition. Type: Grant Filed: August 4, 2016 Date of Patent: May 7, 2019 Assignee: Phibro Animal Health Corporation Inventor: Byoung-Kwan Kim.
  4. Vaccine compositions and methods of treating coronavirus infection Publication number: 20060286124 Abstract: The present disclosure relates to compositions and methods for treating or preventing coronavirus infections. For example, compositions are provided that comprise a coronavirus S protein or N protein, fragment, or variant thereof, capable of eliciting a protective humoral and/or cell-mediated immune response, which compositions are useful for treating or preventing infection by coronavirus, such as the causative agent of SARS. Also, coronavirus S protein and N protein immunogen compositions are provided that include an adjuvant, such as Proteosome or Protollin, which may be used for treating or preventing infection caused by a coronavirus, such as a SARS coronavirus. Type: Application Filed: June 30, 2005 Publication date: December 21, 2006 Applicant: ID Biomedical Corporation of Quebec Inventors: David Burt, Mark Reddish, Mary Hu, George Lowell, David Jones.
  5. Uncharacterized ORF3 in SARS-coronavirus is a cyclic-AMP-dependent kinase and a target for SARS therapy Publication number: 20050276818 Abstract: The present invention relates to novel methods for identifying antiviral agents which selectively interfere with viral proteins that cause the unique infectivity activity of the SARS-coronavirus in comparison to other non-SARS strains of coronavirus. In particular, the present invention relates to screening assays that identify agents which selectively inhibit cyclic-AMP dependent protein kinase activity of the SARS-coronavirus ORF3. The present invention also relates to screening assays that identify agents which selectively inhibit the interaction between SARS-coronavirus cyclic-AMP dependent protein kinase and a calcium dependent targeting molecule. Therefore the agents identified using the assays of the invention may have utility as antiviral agents. The present invention also relates to treatments for sever acute respiratory syndrome caused by a coronavirus, and particularly to treatments that affect the infectivity activity of the SARS-coronavirus. Type: Application Filed: May 17, 2005 Publication date: December 15, 2005 Inventors: Adam Godzik, Sergey Sikora.
  6. Uncharacterized ORF3 in SARS-coronavirus is a cyclic-AMP-dependent kinase and a target for SARS therapy Patent number: 7504205 Abstract: The present invention relates to novel methods for identifying antiviral agents which selectively interfere with viral proteins that cause the unique infectivity activity of the SARS-coronavirus in comparison to other non-SARS strains of coronavirus. In particular, the present invention relates to screening assays that identify agents which selectively inhibit cyclic-AMP dependent protein kinase activity of the SARS-coronavirus ORF3. The present invention also relates to screening assays that identify agents which selectively inhibit the interaction between SARS-coronavirus cyclic-AMP dependent protein kinase and a calcium dependent targeting molecule. Therefore the agents identified using the assays of the invention may have utility as antiviral agents. The present invention also relates to treatments for sever acute respiratory syndrome caused by a coronavirus, and particularly to treatments that affect the infectivity activity of the SARS-coronavirus. Type: Grant Filed: May 17, 2005 Date of Patent: March 17, 2009 Assignee: The Burnham Institute Inventors: Adam Godzik, Sergey Sikora.
  7. Inactivated canine coronavirus vaccine Patent number: 4567042 Abstract: An efficacious parenterally administered inactivated canine coronavirus vaccine which provides systemic, humoral protection and also protection of the intestinal tract in dogs from infection by virulent canine coronavirus is produced. A method for propagation of the canine coronavirus and its attenuation and a method of evaluating the effectiveness of a canine coronavirus vaccine in canines is also disclosed. Type: Grant Filed: June 7, 1984 Date of Patent: January 28, 1986 Assignee: American Home Products Corporation Inventors: William M. Acree, Bobby Edwards, John W. Black.
  8. CANINE RESPIRATORY CORONAVIRUS (CRCV) SPIKE PROTEIN, POLYMERASE AND HEMAGGLUTININ/ESTERASE Publication number: 20090081780 Abstract: A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (e.g., Quebec and LY138) and human coronavirus strain OC43. Type: Application Filed: September 26, 2008 Publication date: March 26, 2009 Applicant: The Royal Veterinary College Inventors: John Brownlie, Victoria Jane Chalker, Kerstin Erles.
  9. PEPTIDE COMPOUNDS FOR DETECTING OR INHIBITING SARS CORONAVIRUS AND APPLICATION THEREOF Publication number: 20100304363 Abstract: Disclosed herein are peptide compounds and the application thereof to the detection and inhibition of SARS coronavirus. Composed of dipeptides, the compounds for detecting and inhibiting SARS coronavirus can be readily synthesized and produced at low cost. In addition, they can be stored safely for a long period of time. The dipeptide compounds are useful as inhibitors of SARS coronavirus as well as acting as excellent capturing materials of SARS coronavirus. Type: Application Filed: May 26, 2010 Publication date: December 2, 2010 Applicant: ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE Inventors: Soo-Hyung LEE, Hyo-Bong Hong, Tao-Wan Kim, Myung-Ae Chung, Sung-Woo Sohn, Seoung-Min Yoo.
  10. Canine Respiratory Coronavirus (Crcv) Spike Protein, Polymerase and Hemagglutinin/Esterase Publication number: 20070248616 Abstract: A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (e.g. Quebec and LY138) and human coronavirus strain OC43. The CRCV spike, polymerase and hemagglutinin/esterase cDNA and protein partial sequences are listed in FIGS. (1) to (4), (13) and (14). Type: Application Filed: July 1, 2003 Publication date: October 25, 2007 Inventors: John Brownlie, Victoria Chalker, Kerstin Erles.
  11. Canine respiratory coronavirus (CRCV) spike protein Patent number: 7981427 Abstract: A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (e.g., Quebec and LY138) and human coronavirus strain OC43. Type: Grant Filed: September 26, 2008 Date of Patent: July 19, 2011 Assignee: The Royal Veterinary College Inventors: John Brownlie, Victoria Jane Chalker, Kerstin Erles.
  12. Methods and compositions for infectious cDNA of SARS coronavirus Publication number: 20060240530 Abstract: The present invention provides a cDNA of a severe acute respiratory syndrome (SARS) coronavirus, recombinant SARS coronavirus vectors, and SARS coronavirus replicon particles. Also provided are methods of making the compositions of this invention and methods of using the compositions as immunogens and/or vaccines and/or to express heterologous nucleic acids. Type: Application Filed: January 19, 2006 Publication date: October 26, 2006 Inventors: Ralph Baric, Rhonda Roberts, Boyd Yount, Kristopher Curtis.
  13. Compositions and methods for detecting severe acute respiratory syndrome coronavirus Publication number: 20050095582 Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus. Type: Application Filed: November 3, 2003 Publication date: May 5, 2005 Applicants: Diagnostic Hybrids, Inc., Health Research Incorporated Inventors: Laura Gillim-Ross, Jill Taylor, David Scholl, David Wentworth, Joseph Jollick Compositions and Methods for Detecting Severe Acute Respiratory Syndrome Coronavirus Publication number: 20080076115 Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus. Type: Application Filed: November 3, 2004 Publication date: March 27, 2008 Inventors: David R. Scholl, Joseph D. Jollick, Laura Gillim-Ross, Jill Taylor, David E. Wentworth.
  14. Compositions And Methods For Detecting Severe Acute Respiratory Syndrome Coronavirus Publication number: 20110223659 Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus. Type: Application Filed: December 7, 2010 Publication date: September 15, 2011 Inventors: David R. Scholl, Joseph D. Jollick, Laura Gillim-Ross, Jill Taylor, David E. Wentworth.
  15. Ribozyme to cleave coronavirus gene Publication number: 20100273997 Abstract: Provided is a ribozyme to cleave a coronavirus gene and a therapeutic agent for a coronavirus infectious disease. A common base sequence in coronaviruses such as SARS-CoV and MHV was searched to design a ribozyme including a base sequence complementary thereto. Moreover, a therapeutic agent for a coronavirus infectious disease including such ribozyme was obtained. Type: Application Filed: August 9, 2006 Publication date: October 28, 2010 Inventors: Noboru Fukuda, Takahiro Ueno, Akiko Fukushima, Kazumichi Kuroda.
  16. Compositions and methods for treating coronavirus infection and SARS Publication number: 20050002901 Abstract: The present invention provides methods of treating a coronavirus infection, and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from a coronavirus infection. The present invention further provides methods of reducing the risk that an individual will develop a pathological coronavirus infection, that has clinical sequelae. The present invention further provides methods of reducing the risk that an individual will develop SARS. The present invention further provides methods of treating SARS. The methods generally involve administering a therapeutically effective amount of a Type I or Type III interferon receptor agonist and/or a Type II interferon receptor agonist for the treatment of a coronavirus infection. Type: Application Filed: March 30, 2004 Publication date: January 6, 2005 Inventor: Lawrence Blatt.
  17. FUSION PROTEINS OF RECOMBINANT SARS CORONAVIRUS STRUCTURAL PROTEINS, THEIR PRODUCTION AND USES Publication number: 20100150923 Abstract: Fusion proteins of recombinant SARS coronavirus structural proteins, their production and uses are provided. An optimized SARS coronavirus S protein gene which can be highly expressed in the mammalian cell strains and SARS coronavirus S protein variants comprising deletion, modification or mutation amino acids 318-510 corresponding to SARS coronavirus S protein are also provided. Type: Application Filed: June 13, 2006 Publication date: June 17, 2010 Applicant: Chinese Academy of Medical Sciences, Institute of Basic Medical Sciences Inventors: Chengyu Jiang, Feng Guo, Shuan Rao, Bing Guan, Yi Huan, Peng Yang.
  18. Civet animal model system for Severe Acute Respiratory Syndrome (SARS) coronavirus infection and uses thereof Publication number: 20060123499 Abstract: The present invention is directed towards the use of the masked palm civet Paguma larvata (“civet”) as an animal model system for SARS, and is based on the novel demonstration of the present invention that civets may be infected with exogenous coronavirus, and that such infection produces SARS-like symptoms in these infected animals. The present invention is directed to a civet model system for the study of the infection, replication, and clinical effects of exogenously introduced human SARS-CoV coronavirus strains, civet SARS-CoV-like coronavirus strains, or variants or derivatives thereof, and to the development of vaccines (or other methods of prevention) or treatment of infection or transmission to other civets or humans of these human SARS-CoV coronavirus strains, civet SARS-CoV-like coronavirus strains, or variants or derivatives thereof. Type: Application Filed: December 6, 2004 Publication date: June 8, 2006 Inventors: Donglai Wu, Xiangang Kong, Qingwen Meng, Yonggang Liu, Yuntao Guan, Xunnan Yin, Mouping Wang, Changwen Li, Ming Liao, Chao-an Xin, Jinding Chen, Changchun Tu, Hua Xuan, Yedong Yu.
  19. METHODS AND COMPOSITIONS FOR CORONAVIRUS DIAGNOSTICS AND THERAPEUTICS Publication number: 20160238601 Abstract: The present invention provides methods and compositions for detecting a coronavirus in a sample and identifying the subgroup of the coronavirus in the sample. Type: Application Filed: October 14, 2014 Publication date: August 18, 2016 Inventors: Ralph Baric, Sudhakar Agnihothram, Boyd Yount

But earlier than we go leaping to conclusions, we must exercise some indispensable questioning and discernment.

What’s the claim?

Well, the implication is that… if the coronavirus used to be patented earlier than the outbreak, used to be the outbreak of a manufactured event? Did they deliberately launch this virus?

To examine a claim, you want to recognize what the declare is saying. You want to be aware of what the matters are that it talks about.

Human coronaviruses are common in the course of the world. Seven distinct coronaviruses, that scientists comprehend of, can infect humans and make them sick. Some human coronaviruses had been recognized many years in the past and some have been recognized recently. Human coronaviruses regularly reason slight to average sickness in human beings worldwide. Two more recent human coronaviruses, MERS-CoV and SARS-CoV, have been acknowledged to often reason extreme illness.

Scientifically, coronavirus is a classification of viruses, inside what’s referred to as a taxonomy, or an arbitrary way of categorizing a set of data.

They are known as coronaviruses due to the fact of their halo-like structure viewed beneath an electron microscope.

What does this mean?

It potential that the patents of coronavirus had been possible for different strains—not the Wuhan strain.

The contemporary title given to coronavirus at hand is 2019-nCoV.

As a way as I can tell, there is no affirmation that the stress inflicting the outbreak is one of the ones patented.

At this point, it’s incredibly probable the patent proof noted above doesn’t apply—it would possibly be for coronaviruses, however, we don’t understand for certain if it’s the Wuhan strain.

Does that imply there is something suspicious probably going on too?

Damn Skippy.

Latest THE PIRBRIGHT INSTITUTE Patents:

 

SOURCES:

https://www.sciencealert.com/here-s-what-scientists-know-so-far-about-the-novel-coronavirus-from-china

https://www.theatlantic.com/health/archive/2012/04/legal-drug-pushing-how-disease-mongers-keep-us-all-doped-up/255247/

https://www.cdc.gov/coronavirus/about/symptoms.htmlhttps://ui.adsabs.harvard.edu/abs/2005Sci…309.1864L/abstract

Related Amazing Coincidence! Coronavirus VACCINE Just Announced

Big Pharma, Big Agri, Big Conspiracy: A New World Order Spin on Drugs and GMOs 1st Edition

Ever wonder why the world’s food supply is controlled by a handful of people? Or wonder why American pharmaceuticals are so expensive? Curious about GMOs or black label warnings? This book is an ode to those who suspect something sinister about the quasi-monopolies of the world’s food and drug corporations. Is this another layer to New World Order advancement? Big Pharma, Big Agri, Big Conspiracy is a collection of legitimate research that might make you think twice about crackpot conspiracies.


Steafon

When on a path of enlightenment, one can't help the desire to share. Intel Mindz is the platform that I've chosen to share. Mindfulness is applicable in every factor of life. Universal Energy is powerful and amazing. It is this energy that I project back out to you and the universe. We are all gods. - Steafon Perry

0 Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

//ofgogoatan.com/afu.php?zoneid=3213464
error: Content is protected !!